---
figid: PMC12238593__41392_2025_2299_Fig4_HTML
figtitle: Genetic alterations driving glioblastoma pathogenesis
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12238593
filename: 41392_2025_2299_Fig4_HTML.jpg
figlink: /pmc/articles/PMC12238593/figure/F4/
number: F4
caption: Genetic alterations driving glioblastoma pathogenesis. The schematic illustrates
  key oncogenic genetic alterations contributing to glioblastoma (GBM) development
  and progression. Receptor tyrosine kinases (RTKs), such as EGFR, PDGFR, FGFR, and
  VGFR, initiate downstream signaling cascades, including the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK
  pathways. Loss of tumor suppressors (e.g., PTEN, CDKN2A, RB1, p53) and overactivation
  of oncogenes (e.g., EGFR, MDM2, CDK4/6, TERT, MYB, SOX2, AREG) promote cell cycle
  progression, proliferation, stemness, survival, angiogenesis, and resistance to
  apoptosis. DNA damage response elements (ATM/ATR-Chk1/Chk2) are activated by radiation
  and chemotherapy (TMZ) but are frequently bypassed in GBM. Downstream transcriptional
  regulators such as MYB and SOX2 further enhance tumor cell plasticity and malignancy.
  Collectively, these alterations reprogram the tumor cell phenotype, driving GBM
  progression and therapy resistance
papertitle: 'Glioblastoma at the crossroads: current understanding and future therapeutic
  horizons'
reftext: Shilpi Singh, et al. Signal Transduct Target Ther. 2025;10(NA).
year: '2025'
doi: 10.1038/s41392-025-02299-4
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group
keywords: Drug development | Prognostic markers
automl_pathway: 0.9011942
figid_alias: PMC12238593__F4
figtype: Figure
redirect_from: /figures/PMC12238593__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12238593__41392_2025_2299_Fig4_HTML.html
  '@type': Dataset
  description: Genetic alterations driving glioblastoma pathogenesis. The schematic
    illustrates key oncogenic genetic alterations contributing to glioblastoma (GBM)
    development and progression. Receptor tyrosine kinases (RTKs), such as EGFR, PDGFR,
    FGFR, and VGFR, initiate downstream signaling cascades, including the PI3K/AKT/mTOR
    and RAS/RAF/MEK/ERK pathways. Loss of tumor suppressors (e.g., PTEN, CDKN2A, RB1,
    p53) and overactivation of oncogenes (e.g., EGFR, MDM2, CDK4/6, TERT, MYB, SOX2,
    AREG) promote cell cycle progression, proliferation, stemness, survival, angiogenesis,
    and resistance to apoptosis. DNA damage response elements (ATM/ATR-Chk1/Chk2)
    are activated by radiation and chemotherapy (TMZ) but are frequently bypassed
    in GBM. Downstream transcriptional regulators such as MYB and SOX2 further enhance
    tumor cell plasticity and malignancy. Collectively, these alterations reprogram
    the tumor cell phenotype, driving GBM progression and therapy resistance
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - KRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - PDGFRB
  - PDGFRA
  - CDKN2A
  - TP53
  - TP63
  - TP73
  - MDM2
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDK2
  - CCNE1
  - CCNE2
  - CDK4
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - RB1
  - RBM45
  - MTOR
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDPF1
  - PTEN
  - E2F1
  - UBE2L3
  - PDK1
  - PDPK1
  - CDC25C
  - RASGRF1
  - CDC25A
  - CDC25B
  - ATM
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - CHEK1
  - CHEK2
  - CDC20
  - SOX2
  - MN1
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - AREG
  - MYB
  - TMZ
  - Nucleus
---
